Published: 1 August 2024
Author(s): Robert M. Swift
Section: Commentary

In this issue of the European Journal of Internal Medicine, Johnson, Addolorato and colleagues [1,2] report the efficacy and safety results of a phase 3, multicenter double-blind placebo-controlled clinical trial of a low dose of the serotonin-3-receptor (5HT3) antagonist, ondansetron (called AD04-ondansetron in this Commentary) in the treatment of 303 participants with DSM V alcohol use disorder (AUD). The study duration was 6 months. In addition to the medication, all participants received a manualized psychosocial alcohol treatment, Brief Behavioral Compliance Enhancement Treatment (BBCET) every two weeks.

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

randomness